Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Profit After Tax (2021 - 2025)

Amylyx Pharmaceuticals has reported Profit After Tax over the past 5 years, most recently at -$33.0 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$33.0 million for Q4 2025, up 12.11% from a year ago — trailing twelve months through Dec 2025 was -$144.7 million (up 52.03% YoY), and the annual figure for FY2025 was -$144.7 million, up 52.03%.
  • Profit After Tax for Q4 2025 was -$33.0 million at Amylyx Pharmaceuticals, up from -$34.4 million in the prior quarter.
  • Over the last five years, Profit After Tax for AMLX hit a ceiling of $22.1 million in Q2 2023 and a floor of -$118.8 million in Q1 2024.
  • Median Profit After Tax over the past 5 years was -$35.1 million (2025), compared with a mean of -$34.2 million.
  • Biggest five-year swings in Profit After Tax: skyrocketed 140.83% in 2023 and later tumbled 7652.0% in 2024.
  • Amylyx Pharmaceuticals' Profit After Tax stood at -$28.3 million in 2021, then tumbled by 50.66% to -$42.7 million in 2022, then surged by 111.08% to $4.7 million in 2023, then plummeted by 893.62% to -$37.5 million in 2024, then grew by 12.11% to -$33.0 million in 2025.
  • The last three reported values for Profit After Tax were -$33.0 million (Q4 2025), -$34.4 million (Q3 2025), and -$41.4 million (Q2 2025) per Business Quant data.